Enterprise Value

5.103B

Cash

1.313B

Avg Qtr Burn

N/A

Short % of Float

2.59%

Insider Ownership

2.42%

Institutional Own.

92.26%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
CABOMETYX (cabozantinib) Details
Solid tumor/s, Renal cell carcinoma, Cancer

Approved

Quarterly sales

Approved

Quarterly sales

COMETRIQ (cabozantinib) Details
Metastatic MTC (Medullary Thyroid Cancer)

Approved

Quarterly sales

CABOMETYX (cabozantinib)+atezolizumab Details
Solid tumor/s, Cancer, Castration-resistant prostate cancer

Big Mover™

Susp. Mover™

Phase 3

Data readout

Zanzalintinib (XL092) Details
Solid tumor/s, Colorectal cancer , Cancer

Phase 3

Interim Update

Cabozantinib + Nivolumab + Ipilimumab Details
Solid tumor/s, Cancer, Kidney cancer

Phase 3

Update

Zanzalintinib (XL092) Details
Solid tumor/s, Colorectal cancer , Cancer

Phase 1b

Interim update

Phase 1

Update